vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Inspire Medical Systems, Inc. (INSP). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $269.1M, roughly 1.8× Inspire Medical Systems, Inc.). Inspire Medical Systems, Inc. runs the higher net margin — 50.6% vs -10.1%, a 60.7% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 12.2%). Inspire Medical Systems, Inc. produced more free cash flow last quarter ($41.8M vs $-69.0M). Over the past eight quarters, Inspire Medical Systems, Inc.'s revenue compounded faster (28.1% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Inspire Medical Systems, Inc. is a medical technology firm that develops, manufactures and commercializes implantable neurostimulation solutions for obstructive sleep apnea. Its core product serves patients intolerant to CPAP therapy, with main markets across North America, Europe, and select Asia-Pacific regions, operating in sleep medicine and otolaryngology segments.

CLOV vs INSP — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.8× larger
CLOV
$487.7M
$269.1M
INSP
Growing faster (revenue YoY)
CLOV
CLOV
+32.5% gap
CLOV
44.7%
12.2%
INSP
Higher net margin
INSP
INSP
60.7% more per $
INSP
50.6%
-10.1%
CLOV
More free cash flow
INSP
INSP
$110.8M more FCF
INSP
$41.8M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
INSP
INSP
Annualised
INSP
28.1%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
INSP
INSP
Revenue
$487.7M
$269.1M
Net Profit
$-49.3M
$136.1M
Gross Margin
86.6%
Operating Margin
-10.1%
17.1%
Net Margin
-10.1%
50.6%
Revenue YoY
44.7%
12.2%
Net Profit YoY
-123.2%
286.4%
EPS (diluted)
$4.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
INSP
INSP
Q4 25
$487.7M
$269.1M
Q3 25
$496.6M
$224.5M
Q2 25
$477.6M
$217.1M
Q1 25
$462.3M
$201.3M
Q4 24
$337.0M
$239.7M
Q3 24
$331.0M
$203.2M
Q2 24
$356.3M
$195.9M
Q1 24
$346.9M
$164.0M
Net Profit
CLOV
CLOV
INSP
INSP
Q4 25
$-49.3M
$136.1M
Q3 25
$-24.4M
$9.9M
Q2 25
$-10.6M
$-3.6M
Q1 25
$-1.3M
$3.0M
Q4 24
$-22.1M
$35.2M
Q3 24
$-9.2M
$18.5M
Q2 24
$7.4M
$9.8M
Q1 24
$-19.2M
$-10.0M
Gross Margin
CLOV
CLOV
INSP
INSP
Q4 25
86.6%
Q3 25
85.8%
Q2 25
84.0%
Q1 25
84.7%
Q4 24
85.0%
Q3 24
24.5%
84.1%
Q2 24
30.3%
84.8%
Q1 24
23.6%
84.9%
Operating Margin
CLOV
CLOV
INSP
INSP
Q4 25
-10.1%
17.1%
Q3 25
-4.9%
4.3%
Q2 25
-2.2%
-1.5%
Q1 25
-0.3%
-0.7%
Q4 24
-6.4%
13.3%
Q3 24
-2.7%
7.0%
Q2 24
2.0%
2.6%
Q1 24
-6.5%
-9.3%
Net Margin
CLOV
CLOV
INSP
INSP
Q4 25
-10.1%
50.6%
Q3 25
-4.9%
4.4%
Q2 25
-2.2%
-1.7%
Q1 25
-0.3%
1.5%
Q4 24
-6.6%
14.7%
Q3 24
-2.8%
9.1%
Q2 24
2.1%
5.0%
Q1 24
-5.5%
-6.1%
EPS (diluted)
CLOV
CLOV
INSP
INSP
Q4 25
$4.57
Q3 25
$0.34
Q2 25
$-0.12
Q1 25
$0.10
Q4 24
$1.17
Q3 24
$0.60
Q2 24
$0.32
Q1 24
$-0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
INSP
INSP
Cash + ST InvestmentsLiquidity on hand
$78.3M
$308.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$781.2M
Total Assets
$541.0M
$907.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
INSP
INSP
Q4 25
$78.3M
$308.3M
Q3 25
$322.6M
Q2 25
$300.9M
Q1 25
$369.2M
Q4 24
$194.5M
$445.5M
Q3 24
$288.0M
$411.0M
Q2 24
$254.8M
$439.7M
Q1 24
$208.3M
$441.4M
Stockholders' Equity
CLOV
CLOV
INSP
INSP
Q4 25
$308.7M
$781.2M
Q3 25
$340.9M
$666.5M
Q2 25
$344.2M
$677.8M
Q1 25
$336.1M
$635.7M
Q4 24
$341.1M
$689.7M
Q3 24
$342.2M
$696.6M
Q2 24
$324.9M
$638.1M
Q1 24
$292.5M
$589.0M
Total Assets
CLOV
CLOV
INSP
INSP
Q4 25
$541.0M
$907.3M
Q3 25
$559.7M
$807.7M
Q2 25
$575.0M
$802.2M
Q1 25
$583.7M
$730.8M
Q4 24
$580.7M
$808.4M
Q3 24
$653.0M
$796.2M
Q2 24
$674.2M
$728.4M
Q1 24
$671.8M
$685.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
INSP
INSP
Operating Cash FlowLast quarter
$-66.9M
$52.5M
Free Cash FlowOCF − Capex
$-69.0M
$41.8M
FCF MarginFCF / Revenue
-14.1%
15.5%
Capex IntensityCapex / Revenue
0.4%
4.0%
Cash ConversionOCF / Net Profit
0.39×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$78.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
INSP
INSP
Q4 25
$-66.9M
$52.5M
Q3 25
$12.1M
$68.5M
Q2 25
$5.4M
$2.7M
Q1 25
$-16.3M
$-6.7M
Q4 24
$34.8M
$69.2M
Q3 24
$50.0M
$52.3M
Q2 24
$44.8M
$-78.0K
Q1 24
$25.9M
$8.9M
Free Cash Flow
CLOV
CLOV
INSP
INSP
Q4 25
$-69.0M
$41.8M
Q3 25
$11.4M
$58.1M
Q2 25
$4.8M
$-6.3M
Q1 25
$-16.5M
$-15.1M
Q4 24
$33.3M
$62.2M
Q3 24
$49.6M
$44.3M
Q2 24
$44.4M
$-12.5M
Q1 24
$25.5M
$-2.8M
FCF Margin
CLOV
CLOV
INSP
INSP
Q4 25
-14.1%
15.5%
Q3 25
2.3%
25.9%
Q2 25
1.0%
-2.9%
Q1 25
-3.6%
-7.5%
Q4 24
9.9%
25.9%
Q3 24
15.0%
21.8%
Q2 24
12.5%
-6.4%
Q1 24
7.3%
-1.7%
Capex Intensity
CLOV
CLOV
INSP
INSP
Q4 25
0.4%
4.0%
Q3 25
0.1%
4.6%
Q2 25
0.1%
4.1%
Q1 25
0.0%
4.2%
Q4 24
0.5%
2.9%
Q3 24
0.1%
3.9%
Q2 24
0.1%
6.3%
Q1 24
0.1%
7.1%
Cash Conversion
CLOV
CLOV
INSP
INSP
Q4 25
0.39×
Q3 25
6.90×
Q2 25
Q1 25
-2.24×
Q4 24
1.96×
Q3 24
2.83×
Q2 24
6.04×
-0.01×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons